A decision support system called GI TARGET may help integrate precision medicine into routine care for patients with gastrointestinal cancer, according to researchers.
Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
The prevalence of advanced colorectal neoplasms was 40% to 50% lower among patients who underwent repeated screening at least 10 years after a negative colonoscopy.
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
The approval was based on data from the phase 2 MOUNTAINEER trial, which included patients with HER2-positive. unresectable or metastatic colorectal cancer.